Nan Fung Group Holdings Ltd Raises Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Nan Fung Group Holdings Ltd boosted its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 118.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 68,943 shares of the company's stock after acquiring an additional 37,358 shares during the period. Bicycle Therapeutics accounts for 0.8% of Nan Fung Group Holdings Ltd's portfolio, making the stock its 26th largest holding. Nan Fung Group Holdings Ltd owned approximately 0.10% of Bicycle Therapeutics worth $965,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC grew its position in shares of Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares in the last quarter. Springhill Fund Asset Management HK Co Ltd bought a new position in Bicycle Therapeutics during the fourth quarter valued at approximately $1,630,000. EntryPoint Capital LLC purchased a new position in Bicycle Therapeutics during the 4th quarter valued at approximately $614,000. Platinum Investment Management Ltd. increased its stake in Bicycle Therapeutics by 13.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 309,059 shares of the company's stock worth $4,327,000 after acquiring an additional 36,910 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in shares of Bicycle Therapeutics by 3.5% during the 4th quarter. Candriam S.C.A. now owns 1,087,876 shares of the company's stock worth $15,230,000 after acquiring an additional 37,278 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Price Performance

Shares of Bicycle Therapeutics stock traded down $0.06 during trading on Wednesday, hitting $8.67. The stock had a trading volume of 625,131 shares, compared to its average volume of 396,250. Bicycle Therapeutics plc has a 12 month low of $6.10 and a 12 month high of $28.67. The firm's fifty day simple moving average is $9.23 and its 200-day simple moving average is $15.32. The stock has a market cap of $599.98 million, a PE ratio of -2.64 and a beta of 1.40.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. During the same quarter last year, the firm posted ($1.16) EPS. The firm's revenue was down 30.2% compared to the same quarter last year. Analysts expect that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BCYC has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Stephens reissued an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC restated a "buy" rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.14.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.